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Abstract 
This narrative review focuses on the topic of tobacco smoking
amongst people with schizophrenia spectrum disorders. We searched
PubMed, PsycInfo and Scopus databases for schizophrenia spectrum
disorders and smoking and included articles about the epidemiology
of tobacco smoking in people with schizophrenia spectrum disorders,
examining the relationship between smoking and mental health. This
narrative review describes that a higher prevalence, frequency and
impact of both high nicotine dependence and its harmful effects in
patients with schizophrenia spectrum disorders compared with those
in the general population. Despite several existent theories, the
reasons for high smoking rates, the high dependence on nicotine and
severity of nicotine withdrawal symptoms are not fully understood.
The main aim of this paper is to inform mental health personnel and
particularly clinical and health psychologists about the impact and
role of tobacco smoking for smokers with schizophrenia spectrum
disorders. 
Prevalence of smoking 
Around 60-90% of people with schizophrenia are estimated to
smoke, compared with 15-24% of the adult general population
(Keltner & Grant, 2006; Ziedonis et al., 2008; Diaz et al., 2009;
Kotov et al., 2010; Dickerson et al., 2013; Smith et al., 2014,
Davies 2014). The difference of 30 percentage points from 60% to
90% is large and may reflect the geographic location of the study
or a different classification system used for schizophrenia spectrum
disorders diagnosis, for example DSM classification used by the
American Psychiatric Association (APA) or International
Classification of Diseases (ICD) classification used by the WHO.
Alternatively, the wide range in prevalence may be due to
methodological differences between studies. As in the general
population, in the study of de Leon & Diaz (2005), more males than
females with schizophrenia were smokers (76% of males vs 50%
of females).
Hughes et al. (1986) reported that people with chronic mental
illness had substantially higher smoking rates than control samples
across age, sex, marital, socioeconomic, and alcohol use subgroups,
and the smoking rate was particularly high (88%) in patients with
schizophrenia.
The association between smoking and mental health conditions
becomes stronger relative to the severity of the mental health
condition, with the highest levels of 70% smoking found in
psychiatric in-patients (RCP, 2013; Jochelson et al., 2007). 
DSM-V (APA, 2013) describes 157 specific diagnoses. It is
therefore important not to view ‘mental health conditions’ as one
group, just as one would not consider ‘physical health’ as one
condition.  It is true that there is a high level of smoking prevalence
amongst individuals with mental health conditions but it varies
according to the actual mental health conditions, e.g. schizophrenia,
anxiety disorders, major depression, bipolar disorder (Caponnetto,
2014). Rates of cigarette smoking amongst adults in the United
States and United Kingdom are two to four times higher in people
with current mood, anxiety, and psychotic disorders than in those
without mental illness (Lasser et al., 2000; RCP, 2013). Between
2004 and 2011, after controlling for risk factors such as income,
education, and employment, current smoking rates dropped from
19.2% to 16.5% in US residents without mental illness but not in
those with mental illness (Cook et al., 2014). 
Smoking behaviour
A study with more than 9000 people with severe psychotic
disorders found that these people had a higher risk of having ever
smoked 100 cigarettes (odds ratio (OR) 4.61, 95% confidence
interval (CI) 4.3 to 4.9) relative to the general population after
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controlling for sex, race, age, and geographical region (Hartz et al.,
2014). 
A meta-analysis of five studies across four countries established
that tobacco smoking was associated with a schizophrenia diagnosis
(OR = 5.9), heavier smoking (ORs ranged 1.9–6.4), higher nicotine
dependence and lower cessation rates compared with general
population controls (de Leon & Diaz, 2005). Even patients with
first-episode psychosis are much more likely to smoke than age-
matched controls, as confirmed in a meta-analysis (OR = 6.04)
(Myles et al., 2012). 
In 2013, Zhang et al. enrolled 244 drug-naive smokers with
schizophrenia and 256 healthy controls matched for gender, age and
education, completed the Fagerström Test for Nicotine Dependence
and showed that smokers with schizophrenia spectrum disorders are
heavier smokers than those without a mental health condition
(Zhang et al., 2013). However, it is important to outline that the
study conducted by Zhang et al., (2013) included exclusively never-
medicated participants presenting with first episode of
schizophrenia. 
In 2005, Tidey et al. enrolled 20 smokers with schizophrenia
spectrum disorder and 20 smokers without psychiatric disorders and
measured their smoking topography.  The participants were matched
on age, gender, daily cigarette rate, years of regular smoking and
nicotine dependence. Tidey et al. (2005) reported that smokers with
schizophrenia spectrum disorders take more frequent puffs and
inhale more carbon monoxide (CO) per traditional cigarette and are
highly dependent on nicotine compared with people in the general
population.  A study by Williams et al (2010a) with 21 participants
(11 with schizophrenia spectrum disorders and 10 without) who
smoked 20-30 traditional cigarettes per day (CPD) found that
smokers with schizophrenia spectrum disorders also extract more
nicotine from their cigarettes compared with controls without
schizophrenia spectrum disorders and have higher levels of nicotine
in their blood after smoking one cigarette (Williams et al., 2010a).
However, these two studies were limited by small sample sizes. A
further study by Williams et al. (2011), using a larger sample,
measured serum nicotine levels and ad libitum smoking behaviour
for 24 + two hours using a topography device in 75 smokers with
schizophrenia compared with 86 control smokers without mental
illness. They reported that smokers with schizophrenia differed from
smokers without schizophrenia in that they took more frequent puffs
per traditional cigarettes smoked, which was associated with greater
nicotine intake, and waited less time between puffs.
Effect of smoking on the mortality and physical
health of people with schizophrenia spectrum dis-
orders
As a result of high smoking rates, people with a mental health
condition also have high mortality rates compared with the general
population. Therefore, quitting smoking is particularly important
for this group since smoking is the single largest contributor to their
reduced life expectancy (Campion et al., 2014). The deleterious
effects of smoking seem particularly pronounced and burdensome
amongst people with schizophrenia (Brown et al., 2000; Kelly et
al., 2011). Smokers with schizophrenia die early from diseases
associated with smoking (15-20 years earlier than the general
population) and this is often due to preventable smoking-related
health conditions rather than suicide (Saha et al., 2007). 
In the United States, results from a  retrospective longitudinal
national review of premature mortality amongst 1,138,853 adults
with schizophrenia demonstrated excess deaths from lung cancer,
cardiovascular and respiratory diseases (Olfson et al., 2015). It is
important to note that the findings from this research showed an
excess of deaths especially due to cardiovascular and respiratory
disease for which traditional cigarette use is a fundamental risk
factor (but not the only one, because the use of other substances,
such as alcohol, was also involved. The authors highlight a number
of limitations in their study such as lack of  considering the side
effects of some antipsychotics, such as Clozapine, on cardiovascular
parameters.
In people with schizophrenia spectrum disorder, the risk of
mortality is doubled (Heiberg et al., 2018). About 50% of deaths in
patients with chronic mental illness are due to tobacco-related
cancers, respiratory diseases, and cardiovascular conditions (Kelly
et al., 2011; Callaghan et al., 2014). Callaghan et al. (2014) found
among individuals hospitalized with a primary psychiatric diagnosis
in the USA from 1990 to 2005,  tobacco-related conditions
comprised approximately 53% (23,620/44,469) of total deaths in
the schizophrenia cohort, 48% (6,004/12,564) in the bipolar cohort,
and 50% (35,729/71,058) in the depression cohort. This included
an increased risk of tobacco-related deaths from cancer
(standardised mortality ratio (SMR) 1.30, 95% CI 1.3–1.4),
cardiovascular disease (SMR 2.46, 95% CI 2.41–2.50) and
respiratory diseases (SMR 2.45, 95% CI 2.41–2.48) (Callaghan et
al., 2014). However, these data refer exclusively to smokers who
received in-patient treatment and cannot be generalized to other
smokers treated as outpatients. Moreover, people with schizophrenia
who smoke have poorer health compared with people with
schizophrenia who do not smoke (Aubin et al., 2012). An increased
rate of smoking amongst subjects with schizophrenia spectrum
disorders contributes to multiple negative health effects compared
with the general population (Beary et al., 2012). Specifically,
several studies have shown that people with schizophrenia spectrum
disorders have a significantly higher prevalence of cancer (Sokal et
al., 2004), respiratory diseases (Sokal et al., 2004; Carney et al.,
2006; Batki et al., 2009; Partti et al., 2015), and CVDs (Sokal et
al., 2004; Carney et al., 2006;  Batki et al., 2009) compared with
the general population (Sokal et al., 2004; Carney et al., 2006;
Batki et al., 2009). A  study conducted by Partti et al. (2015),
showed smokers with schizophrenia had a greater likelihood of
suffering from comorbid chronic obstructive pulmonary disease
(COPD) compared with the general population, reporting an OR of
4.23 (1.61, 11.10). Based on these findings, COPD is more common
in smokers with schizophrenia spectrum disorders compared with
the general population. Other studies have also shown an increased
risk of death from cancer (Tran et al., 2009; Partti et al., 2015) and
cardiovascular disease (Druss et al., 2001; Osborn et al., 2007;
Lawrence et al., 2013) with an approximately 12-fold increased risk
of cardiovascular death in smokers compared with non-smokers
(Kelly et al., 2011).
Effect of smoking on the mental health of people
with schizophrenia spectrum disorders
Amongst smokers with schizophrenia spectrum disorders,
smoking is associated with depressive symptoms, increased
hospitalizations, stress, poor treatment outcomes, low quality of life,
and enhanced psychotic symptoms (Dixon et al., 2007).
In schizophrenia spectrum disorders, smoking traditional
cigarettes is associated with  increased hospitalizations (Ziedonis et
al., 1994). Kobayashi et al. (2010) conducted a retrospective study
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with 460 discharged patients with schizophrenia spectrum disorders
in Japan. Smoking status and hospital psychiatric readmissions were
reviewed and it was observed that psychiatric hospital readmission
rates were significantly higher in smokers with schizophrenia
compared with smokers without schizophrenia (HR = 1.78).
Participants were voluntarily admitted to psychiatric hospitals for
the first time and findings cannot be generalized to other populations
or to people in different stages of this illness. Smoking is also
associated with an increased need for higher psychiatric medication
doses. Cigarette smoking increases the activity of the cytochrome
P450 1A2 (CYP1A2) liver enzyme system, thus reducing the blood
concentrations of many drugs (Sagud et al., 2009) and this process
can also have an impact on antipsychotic medication. A meta-
analysis conducted by Tsuda et al. (2014) found that two commonly
used antipsychotics in the treatment of schizophrenia spectrum
disorders, olanzapine and clozapine, should be increased by 30%
and 50%, respectively, in smokers compared with non-smokers in
order to obtain an equivalent olanzapine or clozapine blood levels.
It has been suggested that smoking could act as a trigger for
mental ill-health (West & Jarvis, 2005). Two recent meta-analyses
conducted respectively by Gurillo et al. (2015) and Hunter et al.
(2018) showed that smokers of traditional cigarettes have an ~two-
fold increased risk of developing schizophrenia spectrum disorders.
Gurillo et al. (2015) included five studies and reported an increased
risk of developing a schizophrenia spectrum disorder in smokers
compared with non-smokers (RR = 2.18; 95% CI 1.23–3.85). Also,
Hunter et al. (2018) included five studies and reported a similar
result (RR = 1.99; 95% CI 1.10–3.61), but in conclusion, further
studies are needed to explore the association between traditional
cigarette smoking as a predictor of developing a schizophrenia
spectrum disorder.
Theory explaining high smoking rates and high
nicotine dependence in smokers with schizophre-
nia spectrum disorders
The reasons for the high frequency of both high smoking
prevalence and high nicotine dependence among patients with
schizophrenia spectrum disorders are incompletely understood.
Illness-related factors, patient-related factors and health service-
related factors have been considered in an attempt to find a reason
for this but have failed to arrive at decisive conclusions. 
Illness-related factors
Studies have presented a number of illness-related reasons for
high smoking rates and high nicotine dependence in smokers with
schizophrenia spectrum disorders.
Nicotine evokes its physiological effects by binding with
nicotine acetylcholine receptors (nAChRs) and strengthens rewards
from brain stimulation; nAChRs also play an essential role in
cognitive processes such as memory and learning (Yann et al., 2008)
and researchers have shown abnormalities of nAChRs in people
with schizophrenia (D’Souza & Markou, 2012; Parikh et al., 2014).
Schizophrenia is linked to elevated dopamine levels in dorsal
striatum and reduced cortical dopamine release (Howes et al.,
2017).  Dopamine is a neurotransmitter influenced by nAChRs
(Albuquerque et al., 2009). All antipsychotic medications act on the
dopaminergic system by blocking dopamine receptors of the D2-
type family (Ellenbroek, 2012). Nicotine increases dopamine levels
in the striatum by stimulating its release via nicotinic receptors and
decreasing its degradation by inhibiting monoamine oxidase A and
B. These produce a stimulation effect and a reduction of anti-
psychotic extrapyramidal side effects (Sagud et al., 2009). It has
been suggested that in people with schizophrenia spectrum
disorders, traditional cigarette smoking is a way to self-medicate by
reducing problems associated with antipsychotic treatment (e.g
extrapyramidal symptoms) and reducing positive and negative
psychotic symptoms (Leonard & Adams, 2006), attempting to
remediate cognitive performances as a result of the underlying
schizophrenia spectrum disorders symptoms and stimulating
attention and working memory (Sacco et al., 2005). 
However, some aspects of the above theories are questionable.
For example, if smoking traditional cigarettes reduces problems
associated with antipsychotic treatment, tobacco consumption in
smokers with schizophrenia should be influenced by changes of
antipsychotic drugs.  Also, smokers and non-smokers with
schizophrenia should show significant differences in their
behaviours in terms of positive and negative symptoms
phenomenology.  
In a recent systematic review and meta-analysis, Huang et al.
(2019) explored the effect of traditional cigarette smoking on
different psychopathological positive and negative symptoms of
schizophrenia. Their meta-analysis of 24 studies examined positive
and negative symptoms scores as assessed by the Positive and
Negative Syndrome Scale (PANSS) or the Scale for the Assessment
of Positive Symptoms (SAPS)  and the Scale for the Assessment of
Negative Symptoms (SANS) in 2322 smokers and 2319 non-
smokers with schizophrenia spectrum disorders and showed that
smokers had more severe positive symptoms than non-smokers
(SMD = 0.33, 95% CI: 0.16 to 0.50, P < 0.001) but did not find any
significant difference between smokers and non-smokers for
negative symptoms (SMD = 0.11, 95% CI: −0.06 to 0.28, P = 0.21).
This systematic review and meta-analysis (Huang et al., 2019) also
investigated extrapyramidal side effects of smokers and non-
smokers with schizophrenia spectrum disorders and showed less
severe extrapyramidal side effects in smokers than non-smokers
(SMD = −0.20, 95% CI: −0.38 to −0.02, P = 0. 03). The strength of
this systematic review and meta-analysis is that it included a large
number of studies; however, it is important to consider that different
diagnostic scales (using different items and therefore producing
different scores) were used.
Kumari & Postma (2005) suggested the smoking rate in people
with schizophrenia increased due to nicotine’s improving effect on
schizophrenia symptoms. Studies have described positive
neurocognitive effects of nicotine in principal cognitive domains
(attention, processing speed, working memory, and psychomotor
abilities) in individuals with cognitively impaired people with
schizophrenia. The association between tobacco addiction and
neurocognitive performance in smokers with schizophrenia
spectrum disorders is unclear. Several studies have demonstrated
that nicotine administration has a role in enhancing cognition in
schizophrenia, particularly for the attention/vigilance domain
(Harris et al., 2004; Smith et al., 2005; Hahn et al., 2013).
Furthermore, these studies assessed several cognitive tests with
different outcomes but the majority failed to control for multiple
comparisons on cognitive assessment and the brief duration of these
studies have not confirmed the long-term benefits to
attention/vigilance. Recently, evidence has demonstrated that
smoking may have a detrimental effect on the working memory
(Lee et al., 2015) and hippocampal volume (Schneider et al., 2014)
of people with schizophrenia. A recent systematic review and meta-
analysis of comparative studies conducted by Wang et al. (2019)
explored cognitive functions in smokers and non-smokers with
schizophrenia spectrum disorders and found that smokers with
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schizophrenia spectrum disorders had lower neurocognitive
performance in cognitive tasks than non-smokers with
schizophrenia spectrum disorders.
Research conducted by Barr et al. (2008a) examined the effect
of transdermal nicotine (14 mg nicotine patches) and placebo in
non-smoking individuals with schizophrenia (n=28) and healthy
controls (n=32) in a within-subject study and showed that nicotine
improved cognitive performance in both groups in terms of
attention, but patients with schizophrenia showed greater
improvement in inhibition and impulse control compared with
healthy controls. In a second study, Jubelt et al. (2008) investigated
the effect of transdermal nicotine on episodic memory performance
in non-smoking individuals with (n=10) and without schizophrenia
(n=12). Compared with placebo control conditions, both groups
increased in processing speed and accuracy in recognising novel
objects but there was a trend for a stronger nicotine-induced effect
in schizophrenic patients in the reduction of false alarms and this is
important considering that memory deficits are associated with
functional impairment in schizophrenia and that impaired novelty
detection has been linked to the positive symptoms of
schizophrenia. However, it’s important to consider that these
findings refer to non-smokers with schizophrenia using nicotine not
delivered by traditional cigarettes. 
Further studies have assessed the impact of nicotine intake on
cognitive function in people with schizophrenia spectrum disorders
(D’Souza & Markou, 2012). Despite the differences in level of
nicotine dependence, severity of nicotine withdrawal, craving and
satiety and method of nicotine administration (gum, transdermal
patch, nicotine nasal spray) amongst participants in several different
research studies, findings suggest nicotine administration has a role
to play in enhancing cognition in schizophrenia, particularly for
attention/vigilance (Harris et al., 2004; Smith et al., 2005; Hahn et
al., 2013). However, none of these studies has used cognitive
psychodiagnostic tools specifically designed for people suffering
from schizophrenia spectrum disorders, such as the Brief
Assessment of Cognition in Schizophrenia (BACS) (Kefee et al.,
2004), or MATRICS Consensus Cognitive Battery (MCCB) scales
(Nuechterlein et al., 2008), but have instead used psychodiagnostic
tools created for the general population such as the Repeatable
Battery for the Assessment of Neuropsychological Status (RBANS)
(Randolph et al., 1998), Spatial Attentional Resource Allocation
Task (SARAT) (Hahn et al., 2006), and Singleton Detection Task
or  Continuous Performance Task (CPT) (Conner, 2000). 
A Spanish study (Aguilar et al., 2005) explored the association
between frequency of smoking and severity of positive symptoms
and number of hospitalisations amongst 250 outpatients with
schizophrenia. Patients were classified into three categories: highly
dependent smokers, mildly dependent smokers and non-smokers.
High PANSS total scores and positive symptoms were less frequent
in mildly dependent smokers than in non-smokers or highly
dependent smokers. The highly dependent smokers had the worst
outcomes.  Aguilar et al. (2005) argued that their data did not
support the self-medication hypothesis but rather suggested a
complex interaction between nicotine dependence and symptoms
of schizophrenia.
The self-medication theory has generated further criticism; for
example Manzella et al. (2015) generated a list of predictions from
the self-medication hypothesis applied to smoking traditional
cigarettes in patients with schizophrenia spectrum disorders and
concluded that further consideration of the neurophysiological data
was needed to resolve the countering effects of nicotine-dopamine
interactions on negative and positive symptoms of schizophrenia.
Secondly, the evidence is contradictory that smokers with
schizophrenia spectrum disorders have fewer signs and symptoms
than non-smoking patients.  Thirdly, there is no information whether
smoking traditional cigarettes reduces undesirable side effects of
antipsychotic pharmacological treatments while leaving unmodified
the positive effects of these drugs.
Environmental and genetic aspects play roles in the aetiology
and progress of nicotine addiction and schizophrenia. Patients
affected by schizophrenia have abnormal expression of certain
genes which are common to nicotine addiction and schizophrenia
disorder (Riley et al., 2000; Mexal et al., 2010; Purcell et al., 2014;
Owen et al., 2016). However, this does not completely explain the
high smoking rates in smokers with schizophrenia spectrum
disorders.
Patient-related factors
Another possible explanation could be that smokers with
schizophrenia spectrum disorders have a subjectively more
rewarding experience when smoking compared with others. For
example, Spring et al. (2003) studied the reward value of smoking
traditional cigarettes (compared with other pleasant activities, e.g.,
eating their favourite candy, seeing a movie, receiving a gift) in
individuals with schizophrenia (n=26) as well as healthy controls
(n=26). All participants were nicotine-dependent, heavy smokers
who had smoked since their teenage years and there were no
differences between groups in the number of cigarettes smoked per
day at baseline (BL). Their findings showed that participants did
not differ in their perception of negative consequences related to
smoking traditional cigarettes. However, smokers with
schizophrenia differed significantly from controls in their evaluation
of positive smoking-related effects. Although they recognized
smoking related disadvantages to the same extent as the general
population, they perceived more benefits and found traditional
cigarettes more appealing than alternative rewards, indicating that
their higher smoking rates are mediated by reward-related
experiences. However, this study only considered that traditional
cigarette smoking, and not exclusively nicotine, had greater reward
value for smokers with schizophrenia. Future research should
differentiate between nicotine and cigarette smoking and its
reinforcing effects associated with sensorial and behavioural impact
on reward perception.
In 298 smokers with psychosis living in the community, Baker
et al. (2007) reported that, compared with general population
samples, patients with psychosis were more likely to indicate that
addiction, stimulation and stress management were reasons for
smoking traditional cigarettes. Greater smoking severity was also
associated with greater perceived stress, poorer overall subjective
quality of life, and lower satisfaction with finances, health, leisure
activities, and social relationships (Dixon 2007). Some people with
schizophrenia perceive that smoking traditional cigarettes helps to
manage stress, whereas heavy smokers report increased stress
levels.
A study of Esterberg & Compton conducted in 2005 used semi-
structured interviews to explore reasons for smoking amongst 12
smokers (ages 19 to 43 years, median 25.5) with schizophrenia
spectrum disorders. Their findings showed many reported perceived
benefits associated with smoking traditional cigarettes, including
that smoking traditional cigarettes was considered important to
decrease anxiety, relieve boredom and increase motivation and
concentration. McCloughen et al. (2003) suggested that high
smoking rates and high nicotine dependence in smokers with
schizophrenia are explained by personal and social factors: many
people with schizophrenia spectrum disorders are unemployed and
inactive, and smoking was reported to relieve boredom and improve
                   Review
No
-co
mm
erc
ial
 us
e o
ly
low self-esteem.
Kelly et al. (2012) examined the perceived consequences and
benefits of cigarette smoking and motivation for quitting in 100
nontreatment-seeking smokers who had schizophrenia or
schizoaffective disorder and 100 people without a psychiatric
disorder. People with schizophrenia reported that cigarette smoking
made socialising easier compared with the control group. They also
had a lower appreciation for health risks associated with cigarette
smoking than controls. Potential health consequences were found
to be a less compelling reason to quit smoking compared with the
control group.  
Health service- and health professionals-related factors
Smoking cigarettes is frequently socially accepted amongst
smokers with schizophrenia spectrum disorders (Trainor & Leavey,
2017; Twyman et al., 2014) and many smokers with schizophrenia
spectrum are not offered smoking cessation treatment from health
professionals (Goldberg, 2010; Trainor et al., 2017). Two studies
found that smokers with schizophrenia spectrum disorders were less
likely to be advised to quit compared with smokers without
schizophrenia spectrum disorders (Briskman et al., 2012; Duffy et
al. 2012). Brown et al. (2015) studied the perceptions of 49 mental
health professionals in providing the “5 A’s” (ask, advise, assess,
assist, arrange) of smoking cessation to smokers with schizophrenia.
Clinicians rated a perceived lack of interest amongst patients and
the impact of delivering the intervention on staff time as the greatest
barriers to smoking cessation in this population. Health service and
mental health professionals have an important role in encouraging
quit attempts and can guide the application of smoking cessation
treatment in clinical practice (Prochaska, 2011) but several mental
health professionals believe stopping smoking traditional cigarettes
may worsen their patients’ condition, and some mental health
professionals feel that they are taking away one of their patients’
only pleasures in life (Ratschen et al., 2009; Johnson et al., 2010);
hence, health service- and health professionals-related barriers are
other possible reasons for high smoking rates in people affected by
schizophrenia spectrum disorders.
Motivation to quit smoking in the general popula-
tion and motivation to quit smoking in people with
schizophrenia spectrum disorders
Generally, motivation is theorised as willingness to change
(Biener & Abrams, 1991) and plays a central role in the smoking
cessation process (Baker et al., 2004). Past and recent studies show
that motivation to quit is a key factor in successful quit rates (Biener
& Abrams, 1991; Jardin & Carpenter, 2012). In relapse prevention
theory (Witkiewitz & Marlatt, 2004), motivation is an important
element in quitting smoking and avoiding relapse.
One theory regarding motivation to quit is “PRIME” theory
(West., 2009). This theory of motivation considers plans, responses,
impulses, motives and evaluations as important factors in
motivation to quit. This theory suggests smokers’ evaluative beliefs
about smoking traditional cigarettes, internal impulses and external
triggers, have an important impact on the decision about smoking
cessation. Another model used to explain motivation to quit
smoking is the Transtheoretical Model (Prochaska & DiClemente,
1983), which assumes that a smoker goes through precontemplation,
contemplation, preparation, action, and maintenance stages of
behaviour, each having a different level of motivation, before
quitting successfully
Data from general population studies indicate that motivation
to quit is strongly related to quit attempts but not to successful
smoking cessation (West et al., 2001; Zhou et al., 2009). However,
other studies have found that higher levels of motivation increase
the likelihood of maintaining smoking cessation (Boardman et al.,
2005; Heppner et al., 2011), implying that there are different
opinions about how motivation to quit relates to successfully
quitting smoking in the general population. A study by Ussher et al.
(2016) addressed how motivation to quit smoking, assessed prior
to a quit attempt in a sample of treatment-seeking smokers,
predicted short-term quit rates at four weeks and medium-term at
six or 12 months abstinence and showed that baseline motivation
to quit was not important in determining the success of quit
attempts.
Studies on motivation to quit traditional cigarettes have been
mainly undertaken with the general population and very few studies
have focused on the motivation to quit in special populations such
as patients affected by schizophrenia spectrum disorders. Siru et al.
(2009) conducted a systematic review of motivation to quit in
people with mental health disorders compared with the general
population. Fourteen studies were identified and people with
psychotic disorders were found to be less motivated to quit smoking
than individuals with depression. Addington et al. (1997) showed,
amongst a sample of 60 smokers with schizophrenia, that more than
50% of the sample were motivated to reduce or to quit smoking
traditional cigarettes and showed the same reasons to reduce or to
quit reported by the general population, principally health worries
and social encouragement. Etter et al. (2004) evaluated the stages
of change in 151 patients with schizophrenia spectrum disorders
compared with 742 people in the general population.  The level of
motivation to quit was similar in both groups. Amongst current
smokers, the distribution of stages of change was similar in patients
with schizophrenia or schizoaffective disorder (precontemplation
79%, contemplation 18%, preparation 3%) and in the general
population sample (74%, 22%, and 4%, p = 0.6). 
As part of an RCT to test the efficacy of bupropion in 41
smokers with schizophrenia, Mann-Wrobel et al. (2011) assessed
motivation and confidence to quit: 61.5% considered quitting in the
next month and 85% in the following six months, with 70%
motivated to quit forever.  However, half of the participants reported
low levels of confidence in quitting. 
Therefore, even though there is evidence that motivation to quit
in smokers with schizophrenia spectrum disorders is quite similar
to those of smokers without mental illness, it is evident that it is
more difficult to help them to quit  (Streck et al., 2018).  Therefore,
additional effective strategies of traditional cigarette smoking
cessation, reduction and THR approach are needed. 
Conclusions
This narrative review included literature about the epidemiology
of tobacco smoking in people with schizophrenia spectrum
disorders, examined the relationship between smoking and mental
health and showed a higher prevalence, frequency and impact of
both high nicotine dependence and its harmful effects in patients
with schizophrenia spectrum disorders compared with the general
population. People with schizophrenia spectrum disorders die on
average earlier than the general population. Despite several existent
theories, the reasons for high smoking rates are not fully understood.
This review highlights the importance of increasing treatment
options for this group of smokers, who find quitting difficult and
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have lower quit rates than the general population. Effective
approaches are urgently needed to address the persistently high
smoking rates in smokers with schizophrenia spectrum disorders.
Smoking cessation or Harm Reduction strategies could help to
further reduce the health, financial and psychosocial parity gap
experienced by this population.
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